Metagenomi Therapeutics (MGX) Price to Book (2024 - 2026)

Metagenomi Therapeutics (MGX) has reported Price to Book for 3 consecutive years, with 0.4 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Book rose 40.79% year-over-year to 0.4 in Q2 2026; TTM through Jun 2026 was 0.4, a 40.79% increase from a year earlier, with the FY2025 full-year figure at 0.38, down 33.19% from the prior year.
• Price to Book was 0.4 for Q2 2026 at Metagenomi Therapeutics, up from 0.37 in the prior quarter.
• Over five years, Price to Book peaked at 0.81 in Q1 2024 and troughed at 0.24 in Q1 2025.
• A 3-year average of 0.44 and a median of 0.39 in 2025 frame the typical range for Price to Book.
• The widest YoY moves for Price to Book: up 57.02% in 2025, down 70.45% in 2025.
• Over 3 years, Price to Book stood at 0.58 in 2024, then slumped by 33.19% to 0.38 in 2025, then increased by 3.92% to 0.4 in 2026.
• The last three Price to Book figures came in at 0.4 (Q2 2026), 0.37 (Q1 2026), and 0.38 (Q4 2025), per Business Quant data.